Edap Tms (EDAP) Stock Price
Edap Tms Price
Over the last 19 years Edap Tms grew revenue by 6.0% annually, reaching 70.75 M EUR. Earnings per share have declined at 15.1% per year over the last 13 years. For Edap Tms, the net margin of -41.5% is down versus 1.6% a few years ago. The consensus 12-month price target for Edap Tms is 3.64 EUR, about 0.1% above where the stock trades today. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
Edap Tms stock price
Edap Tms business model & stock analysis
Frequently asked questions about Edap Tms
The business model of Edap Tms SA revolves around providing innovative medical devices and solutions for the treatment of urology and other diseases. With a focus on High-Intensity Focused Ultrasound (HIFU) technology, Edap Tms SA aims to enhance patient care and offer non-invasive, personalized treatment options. By developing cutting-edge medical devices such as Ablatherm® and Focal One®, the company enables healthcare professionals to perform precise and targeted therapeutic procedures. Edap Tms SA's business model emphasizes continuous research and development to stay at the forefront of medical technology advancements, ultimately improving patient outcomes in urology and beyond.
Edap Tms SA is primarily active in the medical technology industry.
The main competitors of Edap Tms SA in the market include companies such as Intuitive Surgical Inc., Siemens AG, and SonaCare Medical LLC.
Edap Tms SA is a leading global provider of innovative medical devices specializing in therapeutic ultrasound. Established in 1979, the company has a rich history of technological advancements in the field. Edap Tms SA's technology utilizes focused ultrasound waves to precisely treat a range of medical conditions, including urological and musculoskeletal disorders. With decades of experience, the company has earned a strong reputation for its cutting-edge solutions and commitment to improving patient outcomes. Edap Tms SA is dedicated to advancing non-invasive therapies and remains at the forefront of medical technology, consistently delivering groundbreaking solutions to healthcare professionals worldwide.
Some significant milestones that the company Edap Tms SA has achieved include: 1. In 2001, the company received FDA approval for their Ablatherm® High Intensity Focused Ultrasound (HIFU) system for the treatment of prostate cancer. 2. In 2015, Edap Tms SA announced the completion of a landmark study demonstrating the long-term efficacy and safety of their Ablatherm HIFU system. 3. In 2017, the company received FDA clearance for its Focal One® HIFU system, offering a non-invasive treatment option for localized prostate cancer. 4. Edap Tms SA has expanded its market presence globally, with installations of their HIFU systems in over 35 countries worldwide. 5. The company continues to innovate and develop new applications for their HIFU technology, driving advancements in minimally invasive treatments for various medical conditions.
Edap Tms SA is primarily present in several countries and regions. These include the United States, Europe, Asia, and Latin America.
Edap Tms SA represents values of innovation, commitment, and excellence in the field of medical technology. As a global leader in therapeutic ultrasound, Edap Tms SA is dedicated to providing cutting-edge solutions for the treatment of urological conditions. With a strong corporate philosophy centered around patient care and continuous improvement, the company strives to deliver safe and effective medical devices that positively impact patients' lives. By combining advanced technology, scientific expertise, and a customer-centric approach, Edap Tms SA remains at the forefront of advancing minimally invasive therapies in the healthcare industry.
Analysts currently set an average price target of 6.22 EUR for the Edap Tms stock (median: 3.64 EUR), implying +71.0 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Edap Tms stock: 6 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Edap Tms to generate revenue of 41.64 M EUR and earnings per share of -0.77 EUR.
The Edap Tms share (EDAP) is listed on 3 stock exchanges, including: NASDAQ (EDAP), Frankfurt (EDA.F), München (EDA.MU).
The company Edap Tms SA is a global provider of medical systems specializing in advanced medical technologies and products. They focus on two main areas: HIFU and Urology. HIFU stands for High-Intensity Focused Ultrasound and refers to the non-invasive treatment of tumors and other tissue abnormalities. The technology uses focused ultrasound energy to destroy tumor cells without damaging surrounding healthy tissue. Edap Tms SA offers a variety of HIFU systems, including Ablatherm® systems, which can be used for the treatment of prostate cancer as well as other medical conditions such as bladder, kidney, and liver tumors. The company also offers a wide range of urological solutions, including lithotripsy or stone removal technologies. These systems are frequently used by urologists for the removal of kidney stones and other urinary tract disorders. The lithotripsy technology works by using high-frequency sound waves to pulverize the stones into small pieces that can then be naturally passed out of the body. The company also offers other urological treatment solutions, including the "Sonolith i-move" technology, which allows doctors to be more flexible and adjust the device's position to meet the needs of the patient and the physician. These solutions are readily available and offer high-performance portable options for doctors and other users, as well as a wide range of accessories and spare parts. The company primarily distributes its products through a well-established global network of suppliers and distributors that support the demand for this technology worldwide. It also invests heavily in research and development to maintain and expand its market-leading position in non-invasive surgical treatment technologies for tumors and stones. Another important element for Edap Tms SA is its strong partnerships with leading medical institutions and research facilities to provide the latest opportunities and innovations in medical technology. In summary, Edap Tms SA has a highly successful business model that focuses on providing HIFU and urological solutions for the global market. It has a strong presence in this diverse and emerging field, is well-diversified, and supported by strategic partnerships and distributors. The company offers a wide range of products with innovative technologies and is well-positioned to deliver advanced solutions to medical professionals and patients worldwide in the face of the challenges and demands of the current medical landscape.
The expected revenue of Edap Tms is 41.64 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Edap Tms is -28.77 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Edap Tms is currently -4.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Edap Tms stock.
The price-to-sales ratio (P/S) of Edap Tms is currently 3.27. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Edap Tms stock.
The Eulerpool Quality Score for Edap Tms is 2/10.
The ISIN of Edap Tms is US2683111072. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Edap Tms is 908548. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Edap Tms is EDAP. The ticker symbol is used to trade Edap Tms shares on the stock exchange.
Edap Tms stock
Edap Tms Peer Group
Edap Tms Ticker
Edap Tms FIGI
All fundamentals and in-depth analysis of Edap Tms
Our stock analysis for Edap Tms stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edap Tms. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.